Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Infectious Disease · Chagas Disease

Options if You Stop Benznidazole for Side Effects

At a Glance

If severe side effects force you to stop benznidazole, your doctor may pause your treatment, adjust your dose, or switch you to nifurtimox. Stopping early is a common safety measure, and your care team will continue to monitor your long-term heart and digestive health.

If you are struggling with troublesome, persistent, or severe side effects from benznidazole, you have several documented options. Discontinuing this medication is a well-documented reality of treating Chagas disease, especially for adults [1]. Depending on your specific symptoms, your medical team may recommend pausing your treatment to let your body recover, adjusting your dosage, or switching to the alternative Chagas medication, nifurtimox [2][3].

Why Discontinuation is Common

Benznidazole is the standard first-line therapy for Chagas disease, but it causes a high frequency of adverse drug reactions [4][5]. Treatment interruptions or permanent suspensions are very common, particularly among adult patients and women, which may be related to how the drug dosage interacts with adult body weight [1][6].

The most common reasons patients must pause or stop treatment include:

  • Cutaneous reactions (mild to severe allergic skin rashes): This is the most frequent cause for stopping the drug [7][8]. Safety note: If you experience blistering, peeling skin, or sores in your mouth or eyes, stop the medication and seek emergency medical care immediately. Researchers have linked an increased risk of severe rashes to a specific genetic marker (the HLA-B*35 allele); while testing for this gene is not yet standard everywhere, it helps explain why some people react so strongly to the drug [9][10].
  • Hepatotoxicity (liver stress): The medication can cause elevated liver enzymes, which is why routine monitoring with blood tests is critical during your treatment [11].
  • Neurological and hematological issues: Peripheral neuropathy (numbness or tingling in the hands and feet) and thrombocytopenia (severe drops in blood platelets) can occur and usually require medical intervention [2][12]. If you feel new tingling in your extremities, contact your doctor before taking your next dose.

Your Options Moving Forward

Option 1: Pausing Treatment

Your doctor’s first step might simply be to pause your medication [2]. Clinical practice often involves stopping the drug temporarily to prevent mild or moderate side effects from escalating into severe ones [13]. During this pause, your doctor waits for your liver enzymes to return to normal or your skin rash to clear up, sometimes offering allergy medications to help manage your symptoms [11].

Option 2: Adjusting the Dosage

Historically, the standard treatment regimen for benznidazole lasts for 60 days, but researchers and doctors are increasingly recognizing that this full dose can be toxic for many patients [14][15]. While there is no universal consensus yet, clinical studies are exploring lower total doses or intermittent dosing schedules [16][17]. Your doctor may evaluate whether adjusting your dose is a safe strategy for you based on emerging clinical research [18].

Option 3: Switching to Nifurtimox

If benznidazole must be permanently stopped, switching to the alternative drug, nifurtimox, is a common next step [3][5]. However, switching requires careful medical supervision:

  • Recovery time: There is no universally defined “washout period” for switching between the two drugs, but doctors typically wait until your benznidazole side effects have fully resolved (which can take days or weeks) before introducing the new medication [5][3].
  • Different side effects: Nifurtimox has its own side effect profile, most notably causing severe gastrointestinal issues like nausea and loss of appetite [19][20]. Taking nifurtimox with food can help improve how well you tolerate it [21].

What If You Cannot Finish the Full Course?

It is natural to fear that failing to complete the 60-day regimen means your Chagas disease will inevitably progress to heart or digestive failure. However, stopping the drug early due to severe side effects is a necessary safety measure, not a personal failure. In fact, emerging evidence suggests that even shorter courses of benznidazole may still be effective at treating the infection [14][15].

Whether you switch medications or stop entirely, your care team will continue to monitor your heart and digestive health long-term [3]. The goal of medication is to protect your future health without causing dangerous harm today.

Common questions in this guide

When should I stop taking benznidazole immediately?
You should stop taking the medication and seek emergency care immediately if you develop blistering, peeling skin, or sores in your mouth or eyes. Additionally, if you feel new numbness or tingling in your hands and feet, contact your doctor before taking your next dose.
What are my options if benznidazole side effects become too severe?
Your doctor may temporarily pause your treatment to allow your body to recover, lower your dosage, or switch you to an alternative medication called nifurtimox. Medical professionals recognize that managing toxicity is just as important as treating the infection.
If I switch to nifurtimox, what side effects should I expect?
Nifurtimox frequently causes gastrointestinal issues, most commonly nausea and a loss of appetite. Taking this medication with food can help improve your tolerance and minimize these stomach-related symptoms.
What happens if I cannot finish the full 60-day benznidazole treatment?
Stopping early to protect your safety is common and does not mean your condition will inevitably worsen. Recent research suggests shorter courses of the drug may still be effective, and your doctor will closely monitor your heart and digestive health long-term regardless of whether you finish the standard regimen.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.At what specific point, or with which symptoms, should I stop taking benznidazole immediately instead of waiting for my next appointment?
  2. 2.If my rash or numbness forces us to pause treatment, roughly how long will we wait before deciding our next step?
  3. 3.Are there alternative dosing schedules or lower doses we can try that align with recent clinical research on benznidazole toxicity?
  4. 4.If we switch to nifurtimox, what gastrointestinal side effects should I expect, and how can we proactively manage them?
  5. 5.If I cannot finish the full medication course, how will we monitor my heart and digestive health moving forward to ensure I stay healthy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Chagas Disease: Is There an Age Limit for Benznidazole?Do Benznidazole & Nifurtimox Reverse Chagas Heart Damage?Can I Donate Blood After Chagas Treatment?Can I Prevent Passing Chagas Disease to My Baby?Did My Chagas Treatment Work If Antibodies Are Positive?How Do Immunosuppressants Affect Chagas Disease?How Often Should You Get an ECG for Silent Chagas?Is Chagas Disease Contagious From Person to Person?What Are the Digestive Symptoms of Chagas Disease?What Causes a False-Positive Chagas Disease Blood Test?What Is an Apical Aneurysm in Chagas Disease?What is Romaña's Sign in Acute Chagas Disease?What is the Kuschnir Classification for Chagas Disease?Life Expectancy with Silent Phase Chagas DiseaseWhat Is the Risk of Getting Chagas from a Kissing Bug Bite?What Specialists Treat Chagas Disease? | Inciteful MedWhich Family Members Need Chagas Disease Screening?Why Must You Avoid Alcohol During Chagas Treatment?Why Is Chagas Disease Frequently Missed in the US?

References

References (21)
  1. 1

    Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.

    Crespillo-Andújar C, Venanzi-Rullo E, López-Vélez R, et al.

    Drug safety 2018; (41(11)):1035-1048 doi:10.1007/s40264-018-0696-5.

    PMID: 30006773
  2. 2

    What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment.

    Aldasoro E, Posada E, Requena-Méndez A, et al.

    The Journal of antimicrobial chemotherapy 2018; (73(4)):1060-1067 doi:10.1093/jac/dkx516.

    PMID: 29351667
  3. 3

    Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.

    Crespillo-Andújar C, Chamorro-Tojeiro S, Norman F, et al.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018; (24(12)):1344.e1-1344.e4 doi:10.1016/j.cmi.2018.06.006.

    PMID: 29906591
  4. 4

    Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease.

    Vinuesa T, Herráez R, Oliver L, et al.

    The American journal of tropical medicine and hygiene 2017; (97(5)):1469-1476 doi:10.4269/ajtmh.17-0044.

    PMID: 29016287
  5. 5

    Trypanocidal Treatment for Chronic Chagas Disease: Past, Present, and Future.

    Hasslocher-Moreno AM

    Revista da Sociedade Brasileira de Medicina Tropical 2025; (58()):e02422025 doi:10.1590/0037-8682-0242-2025.

    PMID: 41172392
  6. 6

    Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions.

    Silveira GPE, Portela LF, Saavedra LB, et al.

    The Journal of antimicrobial chemotherapy 2025; doi:10.1093/jac/dkaf416.

    PMID: 41277594
  7. 7

    Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.

    Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, et al.

    The Journal of antimicrobial chemotherapy 2017; (72(9)):2596-2601 doi:10.1093/jac/dkx180.

    PMID: 28645201
  8. 8

    Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease-authors' response.

    Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, et al.

    The Journal of antimicrobial chemotherapy 2018; (73(4)):1115-1116 doi:10.1093/jac/dkx505.

    PMID: 29309621
  9. 9

    Association of HLA-B∗35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease.

    Bosch-Nicolau P, Salvador F, Sánchez-Montalvá A, et al.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2022; (28(6)):881.e1-881.e5 doi:10.1016/j.cmi.2021.11.021.

    PMID: 34863919
  10. 10

    Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.

    Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; (61(11)):1688-94 doi:10.1093/cid/civ690.

    PMID: 26265500
  11. 11

    Hepatic changes by benznidazole in a specific treatment for Chagas disease.

    Pavan TBS, Silva JWD, Martins LC, et al.

    PloS one 2018; (13(7)):e0200707 doi:10.1371/journal.pone.0200707.

    PMID: 30028842
  12. 12

    Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease.

    Crespillo-Andújar C, Calbacho Robles M, Norman FF, Pérez-Molina JA

    BMJ case reports 2018; (2018()) doi:10.1136/bcr-2017-223788.

    PMID: 29588298
  13. 13

    Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole.

    Vázquez C, García-Vázquez E, Carrilero B, et al.

    Revista da Sociedade Brasileira de Medicina Tropical 2023; (56()) doi:10.1590/0037-8682-0384-2022.

    PMID: 36700605
  14. 14

    Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA).

    Assmus F, Cruz C, Watson JA, et al.

    PLoS neglected tropical diseases 2025; (19(9)):e0013522 doi:10.1371/journal.pntd.0013522.

    PMID: 40982532
  15. 15

    Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review.

    Frade VP, Simões NS, Couto NRB, et al.

    Revista do Instituto de Medicina Tropical de Sao Paulo 2020; (62()):e52 doi:10.1590/s1678-9946202062052.

    PMID: 32725057
  16. 16

    New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.

    Álvarez MG, Hernández Y, Bertocchi G, et al.

    Antimicrobial agents and chemotherapy 2016; (60(2)):833-7 doi:10.1128/AAC.00745-15.

    PMID: 26596935
  17. 17

    Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.

    Crespillo-Andújar C, López-Vélez R, Trigo E, et al.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020; (26(3)):384.e1-384.e4 doi:10.1016/j.cmi.2019.10.030.

    PMID: 31740423
  18. 18

    Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

    Losada Galván I, Madrid Pascual O, Herrero-Martínez JM, et al.

    The American journal of tropical medicine and hygiene 2019; (100(6)):1477-1481 doi:10.4269/ajtmh.18-0638.

    PMID: 30938285
  19. 19

    Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.

    Forsyth CJ, Hernandez S, Olmedo W, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (63(8)):1056-1062 doi:10.1093/cid/ciw477.

    PMID: 27432838
  20. 20

    Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease.

    Jackson Y, Wyssa B, Chappuis F

    The Journal of antimicrobial chemotherapy 2020; (75(3)):690-696 doi:10.1093/jac/dkz473.

    PMID: 31754690
  21. 21

    Biopharmaceutical Characteristics of Nifurtimox Tablets for Age- and Body Weight-Adjusted Dosing in Patients With Chagas Disease.

    Stass H, Feleder E, Garcia-Bournissen F, et al.

    Clinical pharmacology in drug development 2021; (10(5)):542-555 doi:10.1002/cpdd.871.

    PMID: 33029953

This page provides educational information on managing benznidazole side effects. Always consult your prescribing physician immediately if you experience severe reactions or before discontinuing any medication.

Get notified when new evidence is published on American trypanosomiasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.